Ceftolozane-Tazobactam

DRUG4 trials

Conditions

Bacteremia Caused by Gram-Negative BacteriaBloodstream InfectionCarbapenem Resistant Bacterial InfectionFebrile NeutropeniaHospital Acquired Bacterial PneumoniaMultidrug ResistancePseudomonas AeruginosaPseudomonas Infections

Phase 3

Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

WithdrawnNCT04238390

The University of QueenslandBacteremia Caused by Gram-Negative Bacteria

Start: 2022-01-31End: 2024-12-31Updated: 2022-05-19

Phase 4

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

RecruitingNCT06342115

Beneficência Portuguesa de São PauloFebrile Neutropenia

Start: 2025-03-26End: 2026-12-31Target: 176Updated: 2025-05-02

Optimising TREATment for Severe Gram-Negative Bacterial Infections

RecruitingNCT07004049

National University of SingaporeBloodstream Infection, Carbapenem Resistant Bacterial Infection, Hospital Acquired Bacterial Pneumonia +2

Start: 2025-04-21End: 2028-12-31Target: 600Updated: 2025-06-04

Unknown Phase

Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

NCT03510351

Temple UniversityPseudomonas Aeruginosa, Pseudomonas Infections

Start: 2017-02-01End: 2019-02-28Updated: 2018-04-27

Related Papers

Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial